Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Multisite Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Multisite

Protocol TAPUR
Cancer Type: Multisite
Fast Facts

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Protocol EAY131 - MATCH
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH)

Protocol EAY131 - MATCH Protocol A
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Protocol EAY131 - MATCH Protocol C1
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification

Protocol EAY131 - MATCH Protocol C2
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Protocol EAY131 - MATCH Protocol E
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol E: EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Protocol EAY131 - MATCH Protocol J
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol J: EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers with HER2 Amplification

Protocol EAY131 - MATCH Protocol K2
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.

Protocol EAY131 - MATCH Protocol L
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol L: EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Protocol EAY131 - MATCH Protocol M
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Protocol EAY131 - MATCH Protocol T
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol T: EAY131-T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Protocol EAY131 - MATCH Protocol V
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Protocol EAY131 - MATCH Protocol Z1C
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1C: EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification

Protocol EAY131 - MATCH Protocol Z1E
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions

Protocol EAY131 - MATCH protocol Z1F
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1F: EAY131-Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

Protocol EAY131 - MATCH Protocol Z1G
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Protocol EAY131 - MATCH protocol Z1L
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase II Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations

Protocol EAY131 - MATCH Protocol Z1H
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1H: EAY131-Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

Protocol SWOG S1609 DART
Cancer Type: Rare Tumors
Fast Facts

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol ACCRU 2018-01
Cancer Type: Untreated Solid Tumors
Fast Facts

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A221602
Cancer Type: Cancer Control - Nausea
Fast Facts

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A231601CD
Cancer Type: CCDR
Fast Facts

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol DCP-001
Cancer Type: Multisite - Screening

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 Years of Age at Enrollment.
  2. Standard Risk 1
    Patient must be < 11 Years of Age at Enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 Years of Age at Enrollment.

Protocol COG APEC14B1
Cancer Type: All patients
Fast Facts

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE05N1
Cancer Type: Multisite Long Term Follow-up
Fast Facts

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Protocol COG APEC1621 – MATCH Protocol SC
Cancer Type: Screening
Fast Facts

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Protocol COG APEC1621 - MATCH
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Protocol COG APEC1621 - MATCH Protocol A
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol B
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol C
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex 

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol D
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors


Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol F
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 – MATCH Protocol G
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

Protocol COG APEC1621 – MATCH Protocol H
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 – MATCH Protocol I
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 – MATCH Protocol J
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations dated 11/26/2019

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol K
Cancer Type: Molecular

APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol M
Cancer Type: Molecular

APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations

Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621N
Cancer Type: Molecular

APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG ARST1921
Cancer Type: Other
Fast Facts

COG-ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.